In various inflammatory and immune diseases leukocytes migrate from the vasculature into surrounding tissue, where they participate in the inflammatory response, resulting in tissue damage, swelling, pain and loss of function. This process is a cascade of events wherein the leukocytes adhere first transiently, then firmly to the endothelial cells lining blood vessels, then infiltrate through the vessel wall. Adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), 1) E-selectin 2) and vascular cell adhesion molecule-1 (VCAM-1) 3, 4) are upregulated on the endothelium by interleukin-1 (IL-1) or tumor necrosis factor-a (TNF-a) and mediate steps in this cascade of events. 5, 6) It has also been established that activated lymphocytes play a pivotal role in the development and progression of inflammatory diseases such as rheumatoid arthritis (RA), colitis, psoriasis, multiple sclerosis etc., in which immunological mechanisms are involved. For T cell activation and clonal expansion to occur, in addition to the stimulation of T cell receptor (TCR) with antigen-MHC complex expressed on antigen presenting cells, a costimulatory signal mediated by accessory molecules is also required, and TCR-mediated activation in the absence of such a signal can lead to T cell unresponsiveness. The interactions of adhesion molecules such as lymphocyte function associated antigen-1 (LFA-1)/ICAM-1 [7] [8] [9] [10] and very late antigen-4 (VLA-4)/VCAM-1 11, 12) have been demonstrated to transmit this costimulatory signal, and hence it is expected that interfering with these interactions will lead not only to the inhibition of leukocyte infiltration outlined above, but also to unresponsiveness to antigen. Hence inhibitors of adhesion molecules appear to be an attractive means for both ameliorating the inflammatory response and achieving the long-term modulation of the immune response in autoimmune diseases.
It has been reported that anti-adhesion molecule antibodies are able to ameliorate the inflammatory reaction and immunological parameters in various animal models. 13, 14) In clinical trials a monoclonal antibody to ICAM-1 and an ICAM-1 antisense oligonucleotide showed beneficial effects. [15] [16] [17] [18] A number of inhibitors of cell adhesion molecules, especially ICAM-1, have been disclosed in the literature, however to date no such low-molecular weight compounds have been clinically evaluated. [19] [20] [21] [22] [23] Recently, antagonists of the ICAM-1/LFA-1 interaction and of VLA-4 have also been reported. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] During the course of our search for new orally-active adhesion molecules inhibitors, we discovered the 10H-pyrazino [2,3-b] [1, 4] benzothiazine derivative 7b that inhibits ICAM-1 expression on human umbilical vein endothelial cells (HUVEC) with an IC 50 value of 0.32 mM. In this report we describe our initial structure activity studies which focus on modifications to the piperidine ring of 7b.
Chemistry The 10H-pyrazino [2,3-b] [1, 4] benzothiazine derivatives shown in Tables 1-4 were prepared as shown in Charts 1-3. Compound 2 was synthesized from 4-chloro-3-nitrobenzoic acid 1 by displacement of chloride with sodium disulfide (Na 2 S 2 ), reduction of the nitro group and esterification. 41, 42) These intermediates, including aminothiophenol 2, were unstable to purification. The 10H-pyrazino [2,3-b] [1, 4] benzothiazine ring was constructed by condensation of 2 with 2,3-dichloropyrazine. The reduction of ester 3 with lithium aluminum hydride led to alcohol 4, which on chlorination with methanesufonyl chloride afforded the key 10H-pyrazino [2,3- zyl chloride 5 was condensed with the amines 6a-x, to obtain the target molecules 7a-x.
With the exceptions of 6n and 6p-t, the secondary amines 6a-x are either commercially available or known in the literature. [43] [44] [45] [46] [47] [48] [49] [50] Sulfonamide 6n and sulfamides 6p-r were prepared as shown in Chart 2 by condensation of 4-amino-1-benzylpiperidine with trifluoromethanesulfonic anhydride, N,N-dimethylsulfamoyl chloride or N-methylsulfamoyl chloride 51) or sulfamide, followed by deprotection using 10% palladium on carbon (Pd/C). Sulfamides 6s and 6t were synthesized using the method of G. E. DuBois as shown in Chart 3. 52, 53) Catechol sulfate 10 was condensed with Nbenzyl piperidine to obtain sulfamate ester 11. The key secondary amines 6s and 6t were obtained by coupling of this sulfamate ester 11 with piperidine or morpholine respectively, followed by debenzylation using Pd/C.
Biological Assay
The 10H-pyrazino [2,3-b] [1, 4] benzothiazine derivatives were first evaluated for their inhibitory activity against the expression of adhesion molecules such as ICAM-1 on TNF-a-stimulated HUVEC in vitro. A solution of the test compound was added to HUVEC, which was then stimulated with TNF-a (1 ng/ml) for 4 h. After fixing the HUVEC with glutaraldehyde, ICAM-1 expression on the cell surface was evaluated using an ELISA. 54) For in vitro studies the relative potencies are expressed as IC 50 values. Tests were run in duplicate, and the IC 50 value determinations were performed by the least-squares method using four concentrations of compound.
The effect of the compounds on neutrophil accumulation was next evaluated in a mouse IL-1-induced paw inflammation model. Briefly, the compounds to be tested were orally administered to BALB/c mice 30 min prior to a rat rIL-1 injection. Two hours after this injection, the injected paws were removed and myeloperoxidase (MPO) was measured spectrophotometrically as a marker enzyme for neutrophil content according to a literature method.
55)

Results and Discussion
Initially, the effect of ring size of the cyclic amine in compound 7 was investigated as shown in Table 1 . The azetidine derivative 7a, and 7-or 8-membered-ring (7c, d) compounds were 2-4-fold less active than piperidine 7b. The morpholine derivative 7e and piperazine derivative 7f were also prepared to examine the possibility of introducing a heteroatom at the 4-position of piperidine, but were less active than the parent structure. These results suggest that the 6-memberedring is favorable for activity.
As shown in Table 2 we next turned our attention to substituted piperidine derivatives, examining the optimal position for substitution using the carboxamide group as a probe. The 4-carboxamide 7i showed good activity, with an IC 50 value of 0.69 mM, while the 3-derivative 7h showed a slight loss of activity, with an IC 50 value of 1.02 mM. On the other hand, the 2-carboxamide 7g showed a 17-fold loss in inhibitory activity compared to 7i. These results suggest that steric hindrance around the benzylamine nitrogen is unfavorable. We decided to optimize further at the 4-position of the piperidine.
Next, modification of the carboxamide moiety of 7i was investigated with results shown in Table 3 . Retro-amide 7j was twice as active in vitro as amide 7i, while methanesulfonamide 7k, used as a bioisostere of carboxamide, also showed 2-fold greater inhibitory activity than 7i. We evaluated the inhibitory activity of 7k against neutrophil infiltration in a mouse IL-1-induced paw inflammatory model at an oral dose of 10 mg/kg. In this model, antibody to ICAM-1 (KAT-1) has been found effective in reducing neutrophil infiltration in the IL-1 injected paw (data not shown). It showed significant inhibition of neutrophil migration in this model with an inhibition value of 85.9Ϯ4.0%. Hence, we next focused on sulfonamide derivatives in order to obtain stronger orally-active compounds. Compounds with an alkylene spacer between the piperidine and methanesulfonamide (7l, m) retained potency both in vitro and in vivo. Replacement of the methyl group of compound 7k with a trifluoromethyl group 7n, or phenyl group 7o also led to retention of in vitro potency, but to loss in potency in the IL-1-induced paw model in mice at a dose of 10 mg/kg. These results suggest that the degree of lipophilicity of this terminal portion of compound 7k may be critical for in vivo activity. To evaluate the lipophilicity of our compounds, we calculated their 924 Vol. 50, No. 7 ClogP, the values for 7k, 7n and 7o being 0.67, 2.78 and 2.46 respectively. 56) We speculated that the preferred ClogP value is around 0.6 for these 4-aminopiperidine derivatives and went on to prepare and examine the low ClogP sulfamide derivatives 7p-t shown in Table 3 . In vitro, all these derivatives showed equivalent potency. Of these compounds, the N,N-dimethyl derivative 7p was as active in the IL-1 paw model as the methanesulfonamide 7k. The ClogP value of 7p is also around 0.6, the value suggested above. Furthermore, the morpholinesulfamide 7t showed 66.1Ϯ11.9% inhibition in the IL-1 paw model at 30 mg/kg, while the activity of the equivalent piperidine sulfamide 7s was low. Taken together these results suggest that introduction of a "carrier" sulfonamide or sulfamide moiety into these types of compounds to bring their ClogP to around 0.6 can be an important factor in achieving in vivo activity in the IL-1 paw model.
We next reexamined the piperazine scaffold, preparing amides 7u-x. Carboxamide 7u showed weak activity in vitro compared with the piperidine carboxamide 7j, the same trend as observed in the simple ring compounds 7b and 7f. However, both sulfonamide 7v and sulfamide 7w showed good in vitro activities. These compounds also suppressed neutrophil migration moderately in the IL-1-induced paw inflammation model. 7x, the analog of 7p, showed no inhibitory activity in this model even at a dose of 30 mg/kg. The activities of all the piperazine series were less potent than those of the corresponding piperidine analogues.
The inhibitory activity on other adhesion molecules was studied. The compound 7p suppressed the up-regulation of E-selectin with an IC 50 value of 0.55 mM and that of VCAM-1 with an IC 50 value of 0.36 mM.
The pharmacokinetic characteristics of dimethylsulfamide 7p were also evaluated in fed male rats as shown in Table 5 (10 mg/kg p.o., 3 mg/kg i.v., nϭ3). Compound 7p has a C max of 0.86Ϯ0.17 mM, a mean residence time (MRT ) of 11.4Ϯ2.1 h, and oral bioavailability of 69.0Ϯ1.9%. In this study, the demethyl metabolite, shown as 7q, was also observed with a C max of 0.52Ϯ0.05 mM, and a MRT of 11.4Ϯ 1.7 h.
Conclusion
In order to develop an orally-active inhibitor of adhesion molecules expression, 10H-pyrazino [2,3-b] [1, 4] benzothiazine derivatives were synthesized and their pharmacological properties were evaluated. We found 8-methylpiperidine to be a prefered substituent, and that 4-sulfonamide-and 4-sulfamide-substituted piperidine derivatives showed especially potent in vivo activities. In particular,
significantly inhibited neutrophil migration in the mouse IL-1-induced paw inflammation model after oral administration at a dose of 10 mg/kg. This compound has also good oral bioavailability. This may prove to be valuable therapeutic agent in the treatment of chronic disorders such as rheumatoid arthritis. Efforts to discover novel adhesion molecule inhibitors possessing more potent oral activity are ongoing.
Experimental
Melting points were measured using a Yanako melting-point apparatus and are uncorrected. The proton nuclear magnetic resonance ( 1 H-NMR) spectra were recorded on a Varian Unity 400 (400 MHz) spectrometer, and chemical shifts are expressed in ppm downfield from tetramethylsilane (TMS) as an internal reference. The following abbreviations are used: sϭsinglet, dϭdoublet, tϭtriplet, qϭquartet, mϭmultiplet, brϭbroad. Mass spectra (MS) were obtained on a JEOL JMS-HX100 mass spectrometer. High resolution mass spectra (HR-MS) were obtained on a JEOL JMS-SX102AQQ mass spectrometer. Elemental analysis was performed with a Heraeus Elemental Analyzer CHN-O-RAPID. Materials were used as bought without any special purification. Silica gel (Kieselgel 60, Merck) was used for column chromatography, and silica gel (Kieselgel 60 F 254 , layer thickness 0.25 mm, Merck) for analytical thin layer chromatography (TLC). All organic extracts were dried over anhydrous MgSO 4 , and solvents were removed with a rotary evaporator under reduced pressure.
Methyl 10H-Pyrazino[2,3-b][1,4]benzothiazine-8-carboxylate (3)
To a suspension of 4-chloro-3-nitrobenzoic acid 1 (500 g, 2.46 mol) in ethanol (2250 ml) was added dropwise a solution of sodium hydroxide (67 g, 1.7 mol) in water (125 ml), followed by portion-wise addition of a solution of Na 2 S 2 (prepared from sodium sulfide/9H 2 O (600 g, 2.50 mol) and sulfur (80 g, 2.5 mol)). The resulting mixture was refluxed for 30 min, cooled to room temperature (rt), then filtered to obtain 450 g of a dark-green solid precipitate.
To a suspension of this crude compound (450 g) and tin (1098 g, 9.25 mol) in ethanol (2500 ml) was added dropwise conc.HCl until reaction was complete by TLC. The tin residue was removed by filtration, and the filtrate was evaporated. Conc.HCl and ethanol were added to the residue and filtration of the precipitate gave 270 g of a pale yellow powder.
This powder (270 g) was added to a hydrogen chloride saturated methanol solution (900 ml). The resulting mixture was refluxed for 7 h, then was concentrated in vacuo to give the crude pale yellow solid (320 g).
To a suspension of this solid (320 g, 1.72 mol) in N,N-dimethylformamide (DMF, 320 ml) was added dropwise 2,3-dichloropyrazine (256 g, 1.72 mol). The resulting mixture was stirred at 100°C for 30 min, cooled to rt, and added to 640 ml of water, then the precipitate was filtered off and washed with water and ether to give 128 g of 3 as a yellow powder (20%, from 1). mp 265-268°C. 1 Table 5 . Pharmacokinetic Characteristics of 7p
10 mg/kg, p.o. 9.00Ϯ7.51 0.86Ϯ0.17 11.5Ϯ0.3 11.4Ϯ2.1 69.0Ϯ1.9
MRT is mean residence time. (2.5 l) over 1 h at below 15°C under a nitrogen atmosphere. After completion of addition, the resulting mixture was stirred for 1 h at this temperature, then was cooled with ice-water, and water was added dropwise (40 ml), followed by 15% aqueous sodium hydroxide solution (40 ml), and finally water (120 ml), all at under 20°C. Stirring was continued for a further 30 min, then the reaction mixture were filtered. The aluminum residue was washed well with 4ϫ1 l of THF, then the organic phases were evaporated to give 125 g (70%) of 4 as a yellow crystalline solid. mp 187-189°C. 1 -10H-pyrazino[2,3-b][1,4 ]benzothiazine (5) To a solution of 4 (7.0 g, 30 mmol) and pyridine (6.1 ml, 76 mmol) in DMF (50 ml) was added dropwise methanesulfonyl chloride (5.9 ml, 76 mmol) under nitrogen at 0°C. The resulting mixture was stirred for 1 h at rt, then was poured into a mixture of NaHCO 3 -water-CH 2 Cl 2 , and extracted with ethyl acetate (AcOEt). The extract was washed with brine, dried, and evaporated. The precipitate was washed with ether to give 4.7 g (62%) of 5 as a yellow powder. mp 161-162°C. ) and NEt 3 (9.5 ml, 68 mmol) in toluene (50 ml) was added 4-amino-1-benzylpiperidine (7.7 g, 41 mmol) at 0°C. The reaction mixture was stirred for 12 h at rt, an aqueous solution of K 2 CO 3 was added, and then the mixture was extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on NH silica gel (70% AcOEt-hexane) to afford 9q (3.5 g, 30%) as a colorless solid. mp 135. N-(1-Benzylpiperidin-4-yl)sulfamide (9r) To a solution of 4-amino-1-benzylpiperidine (9.9 g, 52 mmol) in 1,2-dimethoxyethane (50 ml) was added sulfamide (5.0 g, 52 mmol) at rt. The reaction mixture was stirred at 100°C for 10 min and at 130°C for 2 h, then concentrated in vacuo. The residue was chromatographed on NH silica gel (60% AcOEt-hexane) to afford 9r (3.8 g, 27%) as a colorless solid. mp 90-91°C. 1 2-Hydroxyphenyl N-(1-Benzylpiperidin-4-yl)sulfamate (11) This sulfamate was prepared according to the procedure of DuBois. 53) To a solution of 1-benzyl-4-aminopiperidine (9.1 g, 48 mmol) and NEt 3 (5.6 ml, 40 mmol) in DMF (120 ml) was added a solution of catecol sulfate 52) (9.0 g, 52 mmol) in CH 2 Cl 2 (20 ml) at 0°C. The reaction mixture was stirred for 2.5 h at 0°C, poured into a 1% NaCl solution (500 ml), then extracted with Et 2 O. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (5% MeOH-CH 2 Cl 2 ) to afford 11 (17 g 
8-Chloromethyl
N-(1-Benzylpiperidin-4-yl)-N,N-pentamethylenesulfamide (12s)
This sulfamide was prepared according to the procedure of DuBois. 53) A solution of 11 (8.7 g, 24 mmol) and piperidine (2.4 g, 29 mmol) in 1,4-dioxane (50 ml) was refluxed for 4 h under a nitrogen atmosphere. The reaction mixture was allowed to cool and then poured into water, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (4% MeOH-CH 2 Cl 2 ) to afford 12s (4.9 g, 60%) as a pale red solid. mp 82-83°C. .0 mmol) and DMF (20 ml) was stirred at 60°C for 3 h. The resulting mixture was poured into water, and was then extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (5% MeOH-CH 2 Cl 2 ) to give the product (0. 45 0 g ) was added. The flask was then placed under a hydrogen atmosphere and stirred at rt for 12 h. The catalyst was removed by filtration and the filtrate was concentrated to give 6n as a colorless solid (0.9 g, 18%). A mixture of 5 (0.5 g, 2.0 mmol), 6n (0.56 g, 2.4 mmol) and K 2 CO 3 (0.83 g, 6.0 mmol) in DMF (30 ml) was stirred at 60°C for 3 h. The resulting mixture was poured into water, and then extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (2% MeOH-CH 2 N,N-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azapentamethylene]-N,N-dimethylsulfamide (7x) In the same manner as described for the preparation of 7b, 7x was obtained as yellow solid (55%). mp 171-173°C. 1 
Pharmacology
Quantification of Adhesion Molecule Expression on HUVEC by ELISA The quantification of adhesion molecule expression on HUVEC by ELISA was performed according to the methods previously described. 54) The test compounds (or vehicle) were added to confluent HUVEC (Sanko Junyaku, Tokyo, Japan) monolayer cultures in 96 well-plates, and 0.25 h later, the cells were stimulated by the addition of TNF-a (final concentration: 1 ng/ml) or vehicle. After an incubation period of 4 h at 37°C, HUVEC were washed twice with 100 ml of PBS (phosphate-buffered saline), and then fixed with 100 ml of PBS containing 0.025% glutaraldehyde for 5 min at room temperature. After the fixation, the cells were washed three times with 200 ml of PBS containing 0.1% BSA (PBSA). An aliquot of 100 ml of washing buffer containing 1 mg/ml of either mouse anti-human ICAM-1 (R&D, Minneapolis, MN, U.S.A.), mouse anti-human E-selectin (R&D, Minneapolis, MN, U.S.A.), or mouse anti-human VCAM-1 antibody (R&D, Minneapolis, MN, U.S.A.) was added to each well, and then the cells were stored at room temperature. Thirty minutes later, the cells were washed twice with 200 ml of PBSA. An aliquot of 100 ml of peroxidase-conjugated goat antimouse IgG (Fc) polyclonal antibody solution (Cosmo Bio Co., Ltd., Tokyo, Japan) which was diluted (1 : 1000) with washing PBSA, was added to each well. After an incubation period of 30 min at room temperature, the cells were washed three times with 200 ml of washing buffer. An aliquot of 100 ml of TMB substrate solution was applied to each well and, after adequate color development, the reaction was quenched by the addition of 100 ml of 1 M phosphoric acid. The absorbance at wavelength 450 nm was measured using an automated microplate reader. (nϭ2).
IL-1-Induced Paw Inflammation Model in the Mouse
Pathogen-free Balb/c mice (6 week old, Charles River laboratories, Astugi, Japan) were orally dosed with vehicle (0.5% hydroxypropyl methyl cellulose) or the test compounds dissolved or suspended in vehicle. Thirty minutes later, the left hind paw of each mouse was injected subcutaneously with rat recombinant IL-1a (rrIL-1a, obtained in our laboratories) (5 ng/50 ml/site). Two hours post rrIL-1a injection, the animals were sacrificed and the injected paws were removed with scissors. The paws were homogenized with 0.5% hexadecyl trimethylammonium bromide (HTAB) in potassium phosphate buffer (pH 6), and the MPO activities of the homogenates were evaluated using odianisidine-H 2 O 2 , as a marker enzyme for neutrophil content. MPO activity in the inflamed paw tissue was measured by the spectrophotometric method reported previously. 55) (nϭ3).
